Articles tagged ‘atrial fibrillation’

The National Institute for Health and Clinical Excellence (NICE) has issued its final appraisal determination on dronedarone (Multaq) recommending the drug as an option for non-permanent atrial fibrillation (AF) in selected patients. (1)

What is being done to reduce catheter ablation procedure times? How do patients feel about multiple procedures to maintain sinus rhythm? These were among the questions addressed at the 9th Atrial Fibrillation Symposium, Berlin 2010, sponsored by the AFib Alliance . The program has become one of the foremost of its kind in Europe. This report features presentations from many world leaders in cardiac rhythm management.

The scientific faculty, Drs Karl-Heinz Kuck, Carlo Pappone and Michel Haïssaguerre opened the meeting with a provocative sequence of presentations with the goal of answering a series of questions starting with ‘What are we doing about…?’

Biosense Webster has announced that it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO® 3 System-guided radiofrequency ablation using the NAVISTAR®

The National Institute for Health and Clinical Excellence (NICE) published their preliminary decision on 24th December 2009, not to recommend the use of the antiarrhythmic, dronedarone, for the treatment of atrial fibrillation (AF) patients on the NHS. The decision has been met with protests from the medical community, politicians and the heart rhythm charity, Arrhythmia Alliance.

The Birkebeinerski race from the Norwegian town of Rena to the Olympic winter sports resort of Lillehammer takes place on 20 March this year. Recent research now suggest that participants may be at unusually high risk of developing atrial fibrillation.

Urgent coordinated action is needed to avoid the thousands of preventable strokes that leave many atrial fibrillation (AF) patients mentally and physically disabled or dead, every year. A report, How Can We Avoid a Stroke Crisis?, recently launched in the European Parliament by Action for Stroke Prevention, a group of health experts from across Europe, proposes measures to tackle stroke in patients with AF, the most common, sustained abnormal heart rhythm and a major cause of stroke(1).

The Second Pan Asian-Pacific ESC Symposium – Moving Towards a Global Approach to Cardiovascular Disease Management will be held on 27th November at three venues across China.

Findings presented at the European Society of Cardiology (ESC) Congress in Barcelona show that adherence to a Mediterranean Diet and high intake of caffeine favour arrhythmias in people without known cardiac disease and also that patients with high intake of caffeine and coffee are more likely to develop atrial fibrillation

Symptoms of depression are related to cardiovascular mortality even after adjustment for other prognostic indicators in optimally treated patients with comorbid atrial fibrillation (AF) and congestive heart failure (CHF).

It has recently been announced that the U.S. Food and Drug Administration (FDA) has approved the use of dronaderone (Multaq®) for patients with atrial fibrillation (AF) or atrial flutter (AFL). Multaq® is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.